Plessala I, Cawston H, Cortes J, Ajjouri R, et al. Cost-effectiveness analysis of atezolizumab as adjuvant treatment of patients with stage II-IIIA non-small cell lung cancer, PD-L1+>/=50% of tumor cells in France: A modeling study. Lung Cancer 2023;184:107316.
PMID: 37562344